Skip to main
RCEL

RCEL Stock Forecast & Price Target

RCEL Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

AVITA Medical is showing promising signs of growth and potential profitability as a result of their expanding wound care portfolio and integrated platform approach, which aligns with current healthcare trends. Additionally, the company has a strong cash efficiency and decreased operating expenses, leading to a narrower net loss in the fourth quarter and improved financials for the full year. Risks to keep in mind include potential clinical, regulatory, and commercial setbacks, as well as competition and intellectual property issues.

Bears say

AVITA Medical is heavily reliant on its single product, RECELL system, which may limit its potential for growth and increase its risk if the product fails to achieve widespread adoption. The company also faces significant competition in the burn treatment market, which could negatively impact its market share and revenue. With a focus on the US market and limited international sales, AVITA may struggle to diversify its revenue sources and reduce its dependence on the US.

RCEL has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AVITA Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AVITA Medical Inc (RCEL) Forecast

Analysts have given RCEL a Buy based on their latest research and market trends.

According to 3 analysts, RCEL has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AVITA Medical Inc (RCEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.